Data for: A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)
No optimal salvage therapy for relapsed/refractory aggressive histological types of non-Hodgkin lymphoma exists. We explored a combination of single-agent lenalidomide following gemcitabine, rituximab, oxaliplatin combination (“GROC-Rev”) in 33 patients. We observed a response rate of 61% (39% complete response rate) and 3-year overall survival of 47%, superior to previous experience. GROC-Rev is a new salvage regimen with encouraging results.